Literature DB >> 22223753

Met degradation: more than one stone to shoot a receptor down.

Jonathan Lefebvre1, Frédéric Ancot, Catherine Leroy, Ghaffar Muharram, Arnaud Lemière, David Tulasne.   

Abstract

The receptor tyrosine kinase Met and its high-affinity ligand, the hepatocyte growth factor/scatter factor (HGF/SF), are essential to embryonic development. Deregulation of their signaling is associated with tumorigenesis and metastasis, notably through receptor overexpression. It is thus important to understand the mechanisms controlling Met expression. The ligand-dependent internalization of Met and its subsequent degradation in the lysosomal compartment are well described. This process is known to attenuate downstream Met signaling pathways. Yet internalized Met takes part directly in intracellular signaling by chaperoning signaling factors in the course of its trafficking. Furthermore, recent studies describe various new degradation mechanisms of membrane-anchored Met, involving proteolytic cleavages or association with novel partners. Although all these degradations are ligand-independent, they share, to different extents, some common features with canonical HGF/SF-dependent degradation. Interestingly, activated Met variants display resistance to degradation, suggesting defective degradation is involved in tumorigenesis. Conversely, forced degradation of Met through reinduction of one or more degradation pathways is a promising therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223753     DOI: 10.1096/fj.11-197723

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  25 in total

1.  Automated selection of regions of interest for intensity-based FRET analysis of transferrin endocytic trafficking in normal vs. cancer cells.

Authors:  Ronak Talati; Andrew Vanderpoel; Amina Eladdadi; Kate Anderson; Ken Abe; Margarida Barroso
Journal:  Methods       Date:  2013-08-28       Impact factor: 3.608

2.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

3.  Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

Authors:  Kyung Chan Park; Bekesho Geleta; Lionel Yi Wen Leck; Jasmina Paluncic; Shannon Chiang; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

4.  Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.

Authors:  Yutong Zhao; Jing Zhao; Rachel K Mialki; Jianxin Wei; Ernst W Spannhake; Ravi Salgia; Viswanathan Natarajan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-26       Impact factor: 5.464

5.  Core cysteine residues in the Plasminogen-Apple-Nematode (PAN) domain are critical for HGF/c-MET signaling.

Authors:  Debjani Pal; Kuntal De; Carly M Shanks; Kai Feng; Timothy B Yates; Jennifer Morrell-Falvey; Russell B Davidson; Jerry M Parks; Wellington Muchero
Journal:  Commun Biol       Date:  2022-07-01

6.  Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Authors:  Mary J Gray; Peter Kannu; Swarkar Sharma; Christine Neyt; Dongping Zhang; Nandina Paria; Philip B Daniel; Heather Whetstone; Hans-Georg Sprenger; Philipp Hammerschmidt; Angela Weng; Lucie Dupuis; Rebekah Jobling; Roberto Mendoza-Londono; Michael Dray; Peiqiang Su; Megan J Wilson; Raj P Kapur; Edward F McCarthy; Benjamin A Alman; Andrew Howard; Gino R Somers; Christian R Marshall; Simon Manners; Adrienne M Flanagan; Karl E Rathjen; Lori A Karol; Haemish Crawford; David M Markie; Jonathan J Rios; Carol A Wise; Stephen P Robertson
Journal:  Am J Hum Genet       Date:  2015-12-03       Impact factor: 11.025

7.  Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jennifer Weiner; Tony Navas; Yvonne A Evrard; Sonny A Khin; Jiuping Jay Ji; Yiping Zhang; Suzanne Borgel; Thomas D Pfister; Robert J Kinders; Donald P Bottaro; W Marston Linehan; Joseph E Tomaszewski; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2016-03-21       Impact factor: 12.531

8.  Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.

Authors:  Wenyuan Xiong; Manja Friese-Hamim; Andreas Johne; Christopher Stroh; Manfred Klevesath; Gerald S Falchook; David S Hong; Pascal Girard; Samer El Bawab
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-01

9.  Functional consequence of the MET-T1010I polymorphism in breast cancer.

Authors:  Shuying Liu; Funda Meric-Bernstam; Napa Parinyanitikul; Bailiang Wang; Agda K Eterovic; Xiaofeng Zheng; Mihai Gagea; Mariana Chavez-MacGregor; Naoto T Ueno; Xiudong Lei; Wanding Zhou; Lakshmy Nair; Debu Tripathy; Powel H Brown; Gabriel N Hortobagyi; Ken Chen; John Mendelsohn; Gordon B Mills; Ana M Gonzalez-Angulo
Journal:  Oncotarget       Date:  2015-02-20

10.  Stathmin regulates keratinocyte proliferation and migration during cutaneous regeneration.

Authors:  Sabrina Schmitt; Kai Safferling; Kathi Westphal; Manuel Hrabowski; Ute Müller; Peter Angel; Lars Wiechert; Volker Ehemann; Benedikt Müller; Stefan Holland-Cunz; Damian Stichel; Nathalie Harder; Karl Rohr; Günter Germann; Franziska Matthäus; Peter Schirmacher; Niels Grabe; Kai Breuhahn
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.